Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhijuan LinSun Yat-sen UniversityBXBing Xu

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows high CR rate with a chemo-free regimen using obinutuzumab and radiotherapy in R/R DLBCL, indicating improved outcomes.

Key Points

  • High CR rates observed in relapsed/refractory DLBCL patients treated with a combination of radiotherapy and glofitamab.
  • All 9 evaluated patients achieved complete response (CR) after 3 cycles based on Lugano 2014 criteria.
  • Trial employed a chemo-free regimen combining obinutuzumab, GM-CSF, and lenalidomide to enhance T cell function and minimize adverse events.
  • The study highlights the potential of bispecific antibodies and T-cell modulation strategies in managing drug resistance in DLBCL.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deebhttps://doi.org/10.1182/blood-2025-3738
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  2. 2Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations
  3. 3Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma2025
  4. 4Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma2025
  5. 5Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025